Clinical Trials

Today’s research is tomorrow’s treatment! This is particularly true here at the University of Ottawa Heart Institute, where research spans from the laboratory to the patient’s bedside and back.

At any given time, the Heart Institute may have up to 200 active clinical trials, in various stages of the lifecycle of a study. Some projects are conducted only here at the Institute, while others are large national or international projects; some are led by us and others we participate in as a site. Thousands of patients and, in some cases, healthy volunteers, participate in our studies annually. Currently, we have 50 Scientists and Clinician Investigators leading research trials on site.

For more information please contact JoinAStudy@ottawaheart.ca.

Current Clinical Trials at the Heart Institute

Status	Study
Recruiting	A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS Conditions: Atrial Fibrillation Sponsor: Biosense Webster, Inc.
Recruiting	A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS Conditions: Atrial Fibrillation Sponsor: Biosense Webster, Inc.
Recruiting	A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS Conditions: Atrial Fibrillation Sponsor: Biosense Webster, Inc.
Recruiting	A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS Conditions: Atrial Fibrillation Sponsor: Biosense Webster, Inc.
Recruiting	A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS Conditions: Atrial Fibrillation Sponsor: Biosense Webster, Inc.
Recruiting	A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS Conditions: Atrial Fibrillation Sponsor: Biosense Webster, Inc.
Recruiting	The STOP-MED CTRCD Trial Conditions: Heart Failure Cardiotoxicity Cardiac Toxicity Antineoplastics Toxicity Cancer Sponsor: University Health Network, Toronto Unity Health Toronto Hamilton Health Sciences Corporation St. Boniface Hospital University of Alberta University of Ottawa Heart Institute, Canada University College London Hospitals Alberta Health Services, Calgary Brigham and Women's Hospital Baker Heart and Diabetes Institute
Recruiting	The STOP-MED CTRCD Trial Conditions: Heart Failure Cardiotoxicity Cardiac Toxicity Antineoplastics Toxicity Cancer Sponsor: University Health Network, Toronto Unity Health Toronto Hamilton Health Sciences Corporation St. Boniface Hospital University of Alberta University of Ottawa Heart Institute, Canada University College London Hospitals Alberta Health Services, Calgary Brigham and Women's Hospital Baker Heart and Diabetes Institute
Recruiting	The STOP-MED CTRCD Trial Conditions: Heart Failure Cardiotoxicity Cardiac Toxicity Antineoplastics Toxicity Cancer Sponsor: University Health Network, Toronto Unity Health Toronto Hamilton Health Sciences Corporation St. Boniface Hospital University of Alberta University of Ottawa Heart Institute, Canada University College London Hospitals Alberta Health Services, Calgary Brigham and Women's Hospital Baker Heart and Diabetes Institute
Recruiting	The STOP-MED CTRCD Trial Conditions: Heart Failure Cardiotoxicity Cardiac Toxicity Antineoplastics Toxicity Cancer Sponsor: University Health Network, Toronto Unity Health Toronto Hamilton Health Sciences Corporation St. Boniface Hospital University of Alberta University of Ottawa Heart Institute, Canada University College London Hospitals Alberta Health Services, Calgary Brigham and Women's Hospital Baker Heart and Diabetes Institute
Recruiting	The STOP-MED CTRCD Trial Conditions: Heart Failure Cardiotoxicity Cardiac Toxicity Antineoplastics Toxicity Cancer Sponsor: University Health Network, Toronto Unity Health Toronto Hamilton Health Sciences Corporation St. Boniface Hospital University of Alberta University of Ottawa Heart Institute, Canada University College London Hospitals Alberta Health Services, Calgary Brigham and Women's Hospital Baker Heart and Diabetes Institute
Recruiting	The STOP-MED CTRCD Trial Conditions: Heart Failure Cardiotoxicity Cardiac Toxicity Antineoplastics Toxicity Cancer Sponsor: University Health Network, Toronto Unity Health Toronto Hamilton Health Sciences Corporation St. Boniface Hospital University of Alberta University of Ottawa Heart Institute, Canada University College London Hospitals Alberta Health Services, Calgary Brigham and Women's Hospital Baker Heart and Diabetes Institute
Recruiting	Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial Conditions: Non-melanoma Skin Cancer Carcinoma, Squamous Cell Carcinoma, Basal Cell Keratinocyte Carcinoma Sponsor: Women's College Hospital Canadian Institutes of Health Research (CIHR) University Health Network, Toronto NOW Foods
Recruiting	Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial Conditions: Non-melanoma Skin Cancer Carcinoma, Squamous Cell Carcinoma, Basal Cell Keratinocyte Carcinoma Sponsor: Women's College Hospital Canadian Institutes of Health Research (CIHR) University Health Network, Toronto NOW Foods
Recruiting	A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	An Interactive Smartphone Application to Motivate Smokers to Quit Conditions: Smoking Cessation Smoking Behaviors Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	An Interactive Smartphone Application to Motivate Smokers to Quit Conditions: Smoking Cessation Smoking Behaviors Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	An Interactive Smartphone Application to Motivate Smokers to Quit Conditions: Smoking Cessation Smoking Behaviors Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	An Interactive Smartphone Application to Motivate Smokers to Quit Conditions: Smoking Cessation Smoking Behaviors Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease Conditions: Acute Myocardial Infarction Coronary Artery Disease Sponsor: Population Health Research Institute
Recruiting	Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease Conditions: Acute Myocardial Infarction Coronary Artery Disease Sponsor: Population Health Research Institute
Recruiting	Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease Conditions: Acute Myocardial Infarction Coronary Artery Disease Sponsor: Population Health Research Institute
Recruiting	Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease Conditions: Acute Myocardial Infarction Coronary Artery Disease Sponsor: Population Health Research Institute
Recruiting	Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease Conditions: Acute Myocardial Infarction Coronary Artery Disease Sponsor: Population Health Research Institute
Recruiting	Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease Conditions: Acute Myocardial Infarction Coronary Artery Disease Sponsor: Population Health Research Institute
Recruiting	Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease Conditions: Acute Myocardial Infarction Coronary Artery Disease Sponsor: Population Health Research Institute
Recruiting	Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease Conditions: Acute Myocardial Infarction Coronary Artery Disease Sponsor: Population Health Research Institute
Recruiting	A Study to Test Asundexian to Prevent a Clot-related Stroke in Participants After an Acute Ischemic Stroke or High-risk TIA/Mini-stroke (Transient Ischemic Attack) Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack Sponsor: Bayer
Recruiting	A Study to Test Asundexian to Prevent a Clot-related Stroke in Participants After an Acute Ischemic Stroke or High-risk TIA/Mini-stroke (Transient Ischemic Attack) Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack Sponsor: Bayer
Recruiting	A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack Sponsor: Bayer
Recruiting	A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack Sponsor: Bayer
Recruiting	A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack Sponsor: Bayer
Recruiting	A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack Sponsor: Bayer
Recruiting	A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack Sponsor: Bayer
Recruiting	A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack Sponsor: Bayer
Recruiting	A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack Sponsor: Bayer
Recruiting	A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack Sponsor: Bayer
Recruiting	A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack Sponsor: Bayer
Recruiting	A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack Sponsor: Bayer
Recruiting	A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack Sponsor: Bayer
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Conditions: Atopic Dermatitis Sponsor: Amgen
Recruiting	Blood Flow Reserve: Effects After Training With Heavy Inspiratory Exercises Conditions: Coronary Artery Disease Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	Blood Flow Reserve: Effects After Training With Heavy Inspiratory Exercises Conditions: Coronary Artery Disease Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	Blood Flow Reserve: Effects After Training With Heavy Inspiratory Exercises Conditions: Coronary Artery Disease Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	Blood Flow Reserve: Effects After Training With Heavy Inspiratory Exercises Conditions: Coronary Artery Disease Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy Conditions: Cardiomyopathy, Hypertrophic Sponsor: Bristol-Myers Squibb
Recruiting	A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy Conditions: Cardiomyopathy, Hypertrophic Sponsor: Bristol-Myers Squibb
Recruiting	A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome Sponsor: argenx
Recruiting	A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome Sponsor: argenx
Recruiting	A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome Sponsor: argenx
Recruiting	A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome Sponsor: argenx
Recruiting	A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome Sponsor: argenx
Recruiting	A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome Sponsor: argenx
Recruiting	A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome Sponsor: argenx
Recruiting	A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome Sponsor: argenx
Recruiting	A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome Sponsor: argenx
Recruiting	A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome Sponsor: argenx
Recruiting	A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome Sponsor: argenx
Recruiting	A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome Sponsor: argenx
Recruiting	A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome Sponsor: argenx
Recruiting	Active-control Randomised Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery Conditions: Bleeding Cardiac Surgery Patients Sponsor: Octapharma
Recruiting	A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome Sponsor: argenx
Recruiting	Active-control Randomised Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery Conditions: Bleeding Cardiac Surgery Patients Sponsor: Octapharma
Recruiting	A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome Sponsor: argenx
Recruiting	Active-control Randomised Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery Conditions: Bleeding Cardiac Surgery Patients Sponsor: Octapharma
Recruiting	Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Conditions: Triple Negative Breast Cancer PD-L1 Negative Sponsor: Gilead Sciences
Recruiting	Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Conditions: Triple Negative Breast Cancer PD-L1 Negative Sponsor: Gilead Sciences
Recruiting	Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Conditions: Triple Negative Breast Cancer PD-L1 Negative Sponsor: Gilead Sciences
Recruiting	Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Conditions: Triple Negative Breast Cancer PD-L1 Negative Sponsor: Gilead Sciences
Recruiting	Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Conditions: Triple Negative Breast Cancer PD-L1 Negative Sponsor: Gilead Sciences
Recruiting	Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Conditions: Triple Negative Breast Cancer PD-L1 Negative Sponsor: Gilead Sciences
Recruiting	Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Conditions: Triple Negative Breast Cancer PD-L1 Negative Sponsor: Gilead Sciences
Recruiting	Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Conditions: Triple Negative Breast Cancer PD-L1 Negative Sponsor: Gilead Sciences
Recruiting	Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Conditions: Triple Negative Breast Cancer PD-L1 Negative Sponsor: Gilead Sciences
Recruiting	Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Conditions: Triple Negative Breast Cancer PD-L1 Negative Sponsor: Gilead Sciences
Recruiting	Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Conditions: Triple Negative Breast Cancer PD-L1 Negative Sponsor: Gilead Sciences
Recruiting	Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Conditions: Triple Negative Breast Cancer PD-L1 Negative Sponsor: Gilead Sciences
Recruiting	Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Conditions: Triple Negative Breast Cancer PD-L1 Negative Sponsor: Gilead Sciences
Recruiting	Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Conditions: Triple Negative Breast Cancer PD-L1 Negative Sponsor: Gilead Sciences
Recruiting	Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Conditions: Triple Negative Breast Cancer PD-L1 Negative Sponsor: Gilead Sciences
Recruiting	Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Conditions: Triple Negative Breast Cancer PD-L1 Negative Sponsor: Gilead Sciences
Recruiting	Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Conditions: Triple Negative Breast Cancer PD-L1 Negative Sponsor: Gilead Sciences
Recruiting	Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Conditions: Triple Negative Breast Cancer PD-L1 Negative Sponsor: Gilead Sciences
Recruiting	Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card Conditions: Coronary Artery Disease Sponsor: Novartis Pharmaceuticals
Recruiting	Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card Conditions: Coronary Artery Disease Sponsor: Novartis Pharmaceuticals
Recruiting	Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card Conditions: Coronary Artery Disease Sponsor: Novartis Pharmaceuticals
Recruiting	Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card Conditions: Coronary Artery Disease Sponsor: Novartis Pharmaceuticals
Recruiting	Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card Conditions: Coronary Artery Disease Sponsor: Novartis Pharmaceuticals
Recruiting	Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card Conditions: Coronary Artery Disease Sponsor: Novartis Pharmaceuticals
Recruiting	Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card Conditions: Coronary Artery Disease Sponsor: Novartis Pharmaceuticals
Recruiting	Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card Conditions: Coronary Artery Disease Sponsor: Novartis Pharmaceuticals
Recruiting	Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card Conditions: Coronary Artery Disease Sponsor: Novartis Pharmaceuticals
Recruiting	Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card Conditions: Coronary Artery Disease Sponsor: Novartis Pharmaceuticals
Recruiting	Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card Conditions: Coronary Artery Disease Sponsor: Novartis Pharmaceuticals
Recruiting	Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card Conditions: Coronary Artery Disease Sponsor: Novartis Pharmaceuticals
Recruiting	Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card Conditions: Coronary Artery Disease Sponsor: Novartis Pharmaceuticals
Recruiting	CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock Conditions: Shock, Cardiogenic Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock Conditions: Shock, Cardiogenic Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock Conditions: Shock, Cardiogenic Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock Conditions: Shock, Cardiogenic Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock Conditions: Shock, Cardiogenic Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock Conditions: Shock, Cardiogenic Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock Conditions: Shock, Cardiogenic Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock Conditions: Shock, Cardiogenic Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock Conditions: Shock, Cardiogenic Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock Conditions: Shock, Cardiogenic Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	Aggressive Smoking Cessation Trial (ASAP) Conditions: Acute Coronary Syndrome Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Recruiting	Aggressive Smoking Cessation Trial (ASAP) Conditions: Acute Coronary Syndrome Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Recruiting	Aggressive Smoking Cessation Trial (ASAP) Conditions: Acute Coronary Syndrome Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Recruiting	Aggressive Smoking Cessation Trial (ASAP) Conditions: Acute Coronary Syndrome Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Recruiting	Aggressive Smoking Cessation Trial (ASAP) Conditions: Acute Coronary Syndrome Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Recruiting	Aggressive Smoking Cessation Trial (ASAP) Conditions: Acute Coronary Syndrome Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Recruiting	RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW) Conditions: Coronary Artery Disease Sponsor: MedTrace Pharma A/S
Recruiting	RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW) Conditions: Coronary Artery Disease Sponsor: MedTrace Pharma A/S
Recruiting	Randomized Ablation-based AF Rhythm-control Versus Rate-control in Patients With HF and High-burden AF Extend Conditions: Atrial Fibrillation Heart Failure Sponsor: Anthony Tang
Recruiting	Randomized Ablation-based AF Rhythm-control Versus Rate-control in Patients With HF and High-burden AF Extend Conditions: Atrial Fibrillation Heart Failure Sponsor: Anthony Tang
Recruiting	Randomized Ablation-based AF Rhythm-control Versus Rate-control in Patients With HF and High-burden AF Extend Conditions: Atrial Fibrillation Heart Failure Sponsor: Anthony Tang
Recruiting	Randomized Ablation-based AF Rhythm-control Versus Rate-control in Patients With HF and High-burden AF Extend Conditions: Atrial Fibrillation Heart Failure Sponsor: Anthony Tang
Recruiting	Randomized Ablation-based AF Rhythm-control Versus Rate-control in Patients With HF and High-burden AF Extend Conditions: Atrial Fibrillation Heart Failure Sponsor: Anthony Tang
Recruiting	Randomized Ablation-based AF Rhythm-control Versus Rate-control in Patients With HF and High-burden AF Extend Conditions: Atrial Fibrillation Heart Failure Sponsor: Anthony Tang
Recruiting	Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion Conditions: Stroke Patent Foramen Ovale Sponsor: Occlutech International AB
Recruiting	Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion Conditions: Stroke Patent Foramen Ovale Sponsor: Occlutech International AB
Recruiting	Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion Conditions: Stroke Patent Foramen Ovale Sponsor: Occlutech International AB
Recruiting	Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion Conditions: Stroke Patent Foramen Ovale Sponsor: Occlutech International AB
Recruiting	Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion Conditions: Stroke Patent Foramen Ovale Sponsor: Occlutech International AB
Recruiting	Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion Conditions: Stroke Patent Foramen Ovale Sponsor: Occlutech International AB
Recruiting	Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion Conditions: Stroke Patent Foramen Ovale Sponsor: Occlutech International AB
Recruiting	Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion Conditions: Stroke Patent Foramen Ovale Sponsor: Occlutech International AB
Recruiting	Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion Conditions: Stroke Patent Foramen Ovale Sponsor: Occlutech International AB
Recruiting	Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion Conditions: Stroke Patent Foramen Ovale Sponsor: Occlutech International AB
Recruiting	Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion Conditions: Stroke Patent Foramen Ovale Sponsor: Occlutech International AB
Recruiting	A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma Conditions: Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Metastatic Embryonal Rhabdomyosarcoma Metastatic Rhabdomyosarcoma Solid Alveolar Rhabdomyosarcoma Spindle Cell Rhabdomyosarcoma Spindle Cell/Sclerosing Rhabdomyosarcoma Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma Conditions: Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Metastatic Embryonal Rhabdomyosarcoma Metastatic Rhabdomyosarcoma Solid Alveolar Rhabdomyosarcoma Spindle Cell Rhabdomyosarcoma Spindle Cell/Sclerosing Rhabdomyosarcoma Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma Conditions: Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Metastatic Embryonal Rhabdomyosarcoma Metastatic Rhabdomyosarcoma Solid Alveolar Rhabdomyosarcoma Spindle Cell Rhabdomyosarcoma Spindle Cell/Sclerosing Rhabdomyosarcoma Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma Conditions: Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Metastatic Embryonal Rhabdomyosarcoma Metastatic Rhabdomyosarcoma Solid Alveolar Rhabdomyosarcoma Spindle Cell Rhabdomyosarcoma Spindle Cell/Sclerosing Rhabdomyosarcoma Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma Conditions: Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Metastatic Embryonal Rhabdomyosarcoma Metastatic Rhabdomyosarcoma Solid Alveolar Rhabdomyosarcoma Spindle Cell Rhabdomyosarcoma Spindle Cell/Sclerosing Rhabdomyosarcoma Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma Conditions: Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Metastatic Embryonal Rhabdomyosarcoma Metastatic Rhabdomyosarcoma Solid Alveolar Rhabdomyosarcoma Spindle Cell Rhabdomyosarcoma Spindle Cell/Sclerosing Rhabdomyosarcoma Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma Conditions: Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Metastatic Embryonal Rhabdomyosarcoma Metastatic Rhabdomyosarcoma Solid Alveolar Rhabdomyosarcoma Spindle Cell Rhabdomyosarcoma Spindle Cell/Sclerosing Rhabdomyosarcoma Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma Conditions: Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Metastatic Embryonal Rhabdomyosarcoma Metastatic Rhabdomyosarcoma Solid Alveolar Rhabdomyosarcoma Spindle Cell Rhabdomyosarcoma Spindle Cell/Sclerosing Rhabdomyosarcoma Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma Conditions: Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Metastatic Embryonal Rhabdomyosarcoma Metastatic Rhabdomyosarcoma Solid Alveolar Rhabdomyosarcoma Spindle Cell Rhabdomyosarcoma Spindle Cell/Sclerosing Rhabdomyosarcoma Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma Conditions: Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Metastatic Embryonal Rhabdomyosarcoma Metastatic Rhabdomyosarcoma Solid Alveolar Rhabdomyosarcoma Spindle Cell Rhabdomyosarcoma Spindle Cell/Sclerosing Rhabdomyosarcoma Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma Conditions: Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Metastatic Embryonal Rhabdomyosarcoma Metastatic Rhabdomyosarcoma Solid Alveolar Rhabdomyosarcoma Spindle Cell Rhabdomyosarcoma Spindle Cell/Sclerosing Rhabdomyosarcoma Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Conditions: Primary Mediastinal Large B-Cell Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study Conditions: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy Juvenile Myelomonocytic Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Myelodysplastic Syndrome Post Cytotoxic Therapy Myeloid Leukemia Associated With Down Syndrome Sponsor: LLS PedAL Initiative, LLC Children's Oncology Group National Cancer Institute (NCI)
Recruiting	The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study Conditions: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy Juvenile Myelomonocytic Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Myelodysplastic Syndrome Post Cytotoxic Therapy Myeloid Leukemia Associated With Down Syndrome Sponsor: LLS PedAL Initiative, LLC Children's Oncology Group National Cancer Institute (NCI)
Recruiting	The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study Conditions: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy Juvenile Myelomonocytic Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Myelodysplastic Syndrome Post Cytotoxic Therapy Myeloid Leukemia Associated With Down Syndrome Sponsor: LLS PedAL Initiative, LLC Children's Oncology Group National Cancer Institute (NCI)
Recruiting	The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study Conditions: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy Juvenile Myelomonocytic Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Myelodysplastic Syndrome Post Cytotoxic Therapy Myeloid Leukemia Associated With Down Syndrome Sponsor: LLS PedAL Initiative, LLC Children's Oncology Group National Cancer Institute (NCI)
Recruiting	The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study Conditions: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy Juvenile Myelomonocytic Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Myelodysplastic Syndrome Post Cytotoxic Therapy Myeloid Leukemia Associated With Down Syndrome Sponsor: LLS PedAL Initiative, LLC Children's Oncology Group National Cancer Institute (NCI)
Recruiting	The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study Conditions: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy Juvenile Myelomonocytic Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Myelodysplastic Syndrome Post Cytotoxic Therapy Myeloid Leukemia Associated With Down Syndrome Sponsor: LLS PedAL Initiative, LLC Children's Oncology Group National Cancer Institute (NCI)
Recruiting	The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study Conditions: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy Juvenile Myelomonocytic Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Myelodysplastic Syndrome Post Cytotoxic Therapy Myeloid Leukemia Associated With Down Syndrome Sponsor: LLS PedAL Initiative, LLC Children's Oncology Group National Cancer Institute (NCI)
Recruiting	The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study Conditions: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy Juvenile Myelomonocytic Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Myelodysplastic Syndrome Post Cytotoxic Therapy Myeloid Leukemia Associated With Down Syndrome Sponsor: LLS PedAL Initiative, LLC Children's Oncology Group National Cancer Institute (NCI)
Recruiting	The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study Conditions: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy Juvenile Myelomonocytic Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Myelodysplastic Syndrome Post Cytotoxic Therapy Myeloid Leukemia Associated With Down Syndrome Sponsor: LLS PedAL Initiative, LLC Children's Oncology Group National Cancer Institute (NCI)
Recruiting	The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study Conditions: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy Juvenile Myelomonocytic Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Myelodysplastic Syndrome Post Cytotoxic Therapy Myeloid Leukemia Associated With Down Syndrome Sponsor: LLS PedAL Initiative, LLC Children's Oncology Group National Cancer Institute (NCI)
Recruiting	A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma Sponsor: National Cancer Institute (NCI)
Recruiting	Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Conditions: Metastatic Malignant Neoplasm in the Bone Prostate Adenocarcinoma Stage III Prostate Cancer AJCC v8 Stage IIIA Prostate Cancer AJCC v8 Stage IIIB Prostate Cancer AJCC v8 Stage IIIC Prostate Cancer AJCC v8 Stage IVA Prostate Cancer AJCC v8 Sponsor: NRG Oncology National Cancer Institute (NCI)
Recruiting	Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Conditions: Metastatic Malignant Neoplasm in the Bone Prostate Adenocarcinoma Stage III Prostate Cancer AJCC v8 Stage IIIA Prostate Cancer AJCC v8 Stage IIIB Prostate Cancer AJCC v8 Stage IIIC Prostate Cancer AJCC v8 Stage IVA Prostate Cancer AJCC v8 Sponsor: NRG Oncology National Cancer Institute (NCI)
Recruiting	Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Conditions: Metastatic Malignant Neoplasm in the Bone Prostate Adenocarcinoma Stage III Prostate Cancer AJCC v8 Stage IIIA Prostate Cancer AJCC v8 Stage IIIB Prostate Cancer AJCC v8 Stage IIIC Prostate Cancer AJCC v8 Stage IVA Prostate Cancer AJCC v8 Sponsor: NRG Oncology National Cancer Institute (NCI)
Recruiting	Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Conditions: Metastatic Malignant Neoplasm in the Bone Prostate Adenocarcinoma Stage III Prostate Cancer AJCC v8 Stage IIIA Prostate Cancer AJCC v8 Stage IIIB Prostate Cancer AJCC v8 Stage IIIC Prostate Cancer AJCC v8 Stage IVA Prostate Cancer AJCC v8 Sponsor: NRG Oncology National Cancer Institute (NCI)
Recruiting	Watchman for Patients With Atrial Fibrillation Undergoing Transcatheter Mitral Valve Repair (WATCH-TMVR) Conditions: Nonvalvular Atrial Fibrillation Severe Degenerative Mitral Regurgitation Sponsor: Mayo Clinic
Recruiting	STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation Conditions: Atrial Fibrillation Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Montreal Heart Institute
Recruiting	STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation Conditions: Atrial Fibrillation Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Montreal Heart Institute
Recruiting	STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation Conditions: Atrial Fibrillation Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Montreal Heart Institute
Recruiting	STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation Conditions: Atrial Fibrillation Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Montreal Heart Institute
Recruiting	STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation Conditions: Atrial Fibrillation Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Montreal Heart Institute
Recruiting	STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation Conditions: Atrial Fibrillation Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Montreal Heart Institute
Recruiting	STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation Conditions: Atrial Fibrillation Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Montreal Heart Institute
Recruiting	STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation Conditions: Atrial Fibrillation Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Montreal Heart Institute
Recruiting	STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation Conditions: Atrial Fibrillation Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Montreal Heart Institute
Recruiting	A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT Conditions: Anaplastic Kidney Wilms Tumor Recurrent Kidney Wilms Tumor Stage II Kidney Wilms Tumor Stage III Kidney Wilms Tumor Stage IV Kidney Wilms Tumor Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT Conditions: Anaplastic Kidney Wilms Tumor Recurrent Kidney Wilms Tumor Stage II Kidney Wilms Tumor Stage III Kidney Wilms Tumor Stage IV Kidney Wilms Tumor Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT Conditions: Anaplastic Kidney Wilms Tumor Recurrent Kidney Wilms Tumor Stage II Kidney Wilms Tumor Stage III Kidney Wilms Tumor Stage IV Kidney Wilms Tumor Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT Conditions: Anaplastic Kidney Wilms Tumor Recurrent Kidney Wilms Tumor Stage II Kidney Wilms Tumor Stage III Kidney Wilms Tumor Stage IV Kidney Wilms Tumor Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT Conditions: Anaplastic Kidney Wilms Tumor Recurrent Kidney Wilms Tumor Stage II Kidney Wilms Tumor Stage III Kidney Wilms Tumor Stage IV Kidney Wilms Tumor Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure Conditions: Hemorrhage Urgent Surgery Invasive Procedure Sponsor: SFJ Pharmaceuticals, Inc.
Recruiting	Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure Conditions: Hemorrhage Urgent Surgery Invasive Procedure Sponsor: SFJ Pharmaceuticals, Inc.
Recruiting	Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure Conditions: Hemorrhage Urgent Surgery Invasive Procedure Sponsor: SFJ Pharmaceuticals, Inc.
Recruiting	Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure Conditions: Hemorrhage Urgent Surgery Invasive Procedure Sponsor: SFJ Pharmaceuticals, Inc.
Recruiting	Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure Conditions: Hemorrhage Urgent Surgery Invasive Procedure Sponsor: SFJ Pharmaceuticals, Inc.
Recruiting	Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure Conditions: Hemorrhage Urgent Surgery Invasive Procedure Sponsor: SFJ Pharmaceuticals, Inc.
Recruiting	Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure Conditions: Hemorrhage Urgent Surgery Invasive Procedure Sponsor: SFJ Pharmaceuticals, Inc.
Recruiting	Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure Conditions: Hemorrhage Urgent Surgery Invasive Procedure Sponsor: SFJ Pharmaceuticals, Inc.
Recruiting	Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension Conditions: Pulmonary Arterial Hypertension Sponsor: Actelion
Recruiting	Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension Conditions: Pulmonary Arterial Hypertension Sponsor: Actelion
Recruiting	Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension Conditions: Pulmonary Arterial Hypertension Sponsor: Actelion
Recruiting	Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension Conditions: Pulmonary Arterial Hypertension Sponsor: Actelion
Recruiting	Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension Conditions: Pulmonary Arterial Hypertension Sponsor: Actelion
Recruiting	Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension Conditions: Pulmonary Arterial Hypertension Sponsor: Actelion
Recruiting	Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension Conditions: Pulmonary Arterial Hypertension Sponsor: Actelion
Recruiting	Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension Conditions: Pulmonary Arterial Hypertension Sponsor: Actelion
Recruiting	Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension Conditions: Pulmonary Arterial Hypertension Sponsor: Actelion
Recruiting	Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension Conditions: Pulmonary Arterial Hypertension Sponsor: Actelion
Recruiting	Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension Conditions: Pulmonary Arterial Hypertension Sponsor: Actelion
Recruiting	Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension Conditions: Pulmonary Arterial Hypertension Sponsor: Actelion
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Sponsor: National Cancer Institute (NCI)
Recruiting	Amplatzer Amulet LAAO vs. NOAC Conditions: Atrial Fibrillation Stroke Bleeding Sponsor: Abbott Medical Devices
Recruiting	Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease Sponsor: Edwards Lifesciences
Recruiting	Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease Sponsor: Edwards Lifesciences
Recruiting	Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease Sponsor: Edwards Lifesciences
Recruiting	Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease Sponsor: Edwards Lifesciences
Recruiting	Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease Sponsor: Edwards Lifesciences
Recruiting	Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease Sponsor: Edwards Lifesciences
Recruiting	Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease Sponsor: Edwards Lifesciences
Recruiting	Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease Sponsor: Edwards Lifesciences
Recruiting	Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease Sponsor: Edwards Lifesciences
Recruiting	Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease Sponsor: Edwards Lifesciences
Recruiting	Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease Sponsor: Edwards Lifesciences
Recruiting	Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease Sponsor: Edwards Lifesciences
Recruiting	Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease Sponsor: Edwards Lifesciences
Recruiting	Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease Sponsor: Edwards Lifesciences
Recruiting	MRI Assessment of Pulmonary Edema in Acute Heart Failure Conditions: Acute Heart Failure Pulmonary Edema With Heart Failure Sponsor: University of Alberta Canadian Institutes of Health Research (CIHR)
Recruiting	MRI Assessment of Pulmonary Edema in Acute Heart Failure Conditions: Acute Heart Failure Pulmonary Edema With Heart Failure Sponsor: University of Alberta Canadian Institutes of Health Research (CIHR)
Recruiting	MRI Assessment of Pulmonary Edema in Acute Heart Failure Conditions: Acute Heart Failure Pulmonary Edema With Heart Failure Sponsor: University of Alberta Canadian Institutes of Health Research (CIHR)
Recruiting	MRI Assessment of Pulmonary Edema in Acute Heart Failure Conditions: Acute Heart Failure Pulmonary Edema With Heart Failure Sponsor: University of Alberta Canadian Institutes of Health Research (CIHR)
Recruiting	MRI Assessment of Pulmonary Edema in Acute Heart Failure Conditions: Acute Heart Failure Pulmonary Edema With Heart Failure Sponsor: University of Alberta Canadian Institutes of Health Research (CIHR)
Recruiting	Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery Conditions: Stroke Atrial Fibrillation Sponsor: Population Health Research Institute Hamilton Health Sciences Corporation
Recruiting	Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery Conditions: Stroke Atrial Fibrillation Sponsor: Population Health Research Institute Hamilton Health Sciences Corporation
Recruiting	Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery Conditions: Stroke Atrial Fibrillation Sponsor: Population Health Research Institute Hamilton Health Sciences Corporation
Recruiting	Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery Conditions: Stroke Atrial Fibrillation Sponsor: Population Health Research Institute Hamilton Health Sciences Corporation
Recruiting	Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery Conditions: Stroke Atrial Fibrillation Sponsor: Population Health Research Institute Hamilton Health Sciences Corporation
Recruiting	Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery Conditions: Stroke Atrial Fibrillation Sponsor: Population Health Research Institute Hamilton Health Sciences Corporation
Recruiting	Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Central Nervous System Leukemia Mixed Phenotype Acute Leukemia Testicular Leukemia Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Central Nervous System Leukemia Mixed Phenotype Acute Leukemia Testicular Leukemia Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Central Nervous System Leukemia Mixed Phenotype Acute Leukemia Testicular Leukemia Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Central Nervous System Leukemia Mixed Phenotype Acute Leukemia Testicular Leukemia Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Central Nervous System Leukemia Mixed Phenotype Acute Leukemia Testicular Leukemia Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF) Conditions: Intracranial Hemorrhages Atrial Fibrillation Sponsor: Population Health Research Institute
Recruiting	EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF) Conditions: Intracranial Hemorrhages Atrial Fibrillation Sponsor: Population Health Research Institute
Recruiting	EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF) Conditions: Intracranial Hemorrhages Atrial Fibrillation Sponsor: Population Health Research Institute
Recruiting	EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF) Conditions: Intracranial Hemorrhages Atrial Fibrillation Sponsor: Population Health Research Institute
Recruiting	EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF) Conditions: Intracranial Hemorrhages Atrial Fibrillation Sponsor: Population Health Research Institute
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome Sponsor: National Cancer Institute (NCI)
Recruiting	TRILUMINATE Pivotal Trial Conditions: Tricuspid Regurgitation Sponsor: Abbott Medical Devices
Recruiting	TRILUMINATE Pivotal Trial Conditions: Tricuspid Regurgitation Sponsor: Abbott Medical Devices
Recruiting	TRILUMINATE Pivotal Trial Conditions: Tricuspid Regurgitation Sponsor: Abbott Medical Devices
Recruiting	TRILUMINATE Pivotal Trial Conditions: Tricuspid Regurgitation Sponsor: Abbott Medical Devices
Recruiting	TRILUMINATE Pivotal Trial Conditions: Tricuspid Regurgitation Sponsor: Abbott Medical Devices
Recruiting	Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia Conditions: Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia Conditions: Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia Conditions: Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia Conditions: Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia Conditions: Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Effect of a Hybrid Rehabilitation Program on Walking, Quality of Life & Cardiovascular Risk in People With PAD Conditions: Peripheral Arterial Disease Sponsor: Ottawa Heart Institute Research Corporation AFP Innovation Fund
Recruiting	Effect of a Hybrid Rehabilitation Program on Walking, Quality of Life & Cardiovascular Risk in People With PAD Conditions: Peripheral Arterial Disease Sponsor: Ottawa Heart Institute Research Corporation AFP Innovation Fund
Recruiting	Effect of a Hybrid Rehabilitation Program on Walking, Quality of Life & Cardiovascular Risk in People With PAD Conditions: Peripheral Arterial Disease Sponsor: Ottawa Heart Institute Research Corporation AFP Innovation Fund
Recruiting	Effect of a Hybrid Rehabilitation Program on Walking, Quality of Life & Cardiovascular Risk in People With PAD Conditions: Peripheral Arterial Disease Sponsor: Ottawa Heart Institute Research Corporation AFP Innovation Fund
Recruiting	Effect of a Hybrid Rehabilitation Program on Walking, Quality of Life & Cardiovascular Risk in People With PAD Conditions: Peripheral Arterial Disease Sponsor: Ottawa Heart Institute Research Corporation AFP Innovation Fund
Recruiting	Effect of a Hybrid Rehabilitation Program on Walking, Quality of Life & Cardiovascular Risk in People With PAD Conditions: Peripheral Arterial Disease Sponsor: Ottawa Heart Institute Research Corporation AFP Innovation Fund
Recruiting	Effect of a Hybrid Rehabilitation Program on Walking, Quality of Life & Cardiovascular Risk in People With PAD Conditions: Peripheral Arterial Disease Sponsor: Ottawa Heart Institute Research Corporation AFP Innovation Fund
Recruiting	Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance Conditions: Ascending Aortic Aneurysm Enlargement Ascending Aorta Aneurysm Sponsor: Ottawa Heart Institute Research Corporation University of Calgary
Recruiting	Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance Conditions: Ascending Aortic Aneurysm Enlargement Ascending Aorta Aneurysm Sponsor: Ottawa Heart Institute Research Corporation University of Calgary
Recruiting	Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance Conditions: Ascending Aortic Aneurysm Enlargement Ascending Aorta Aneurysm Sponsor: Ottawa Heart Institute Research Corporation University of Calgary
Recruiting	Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance Conditions: Ascending Aortic Aneurysm Enlargement Ascending Aorta Aneurysm Sponsor: Ottawa Heart Institute Research Corporation University of Calgary
Recruiting	Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer Conditions: Breast Cancer Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting	Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer Conditions: Breast Cancer Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting	Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer Conditions: Breast Cancer Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting	Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer Conditions: Breast Cancer Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting	Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer Conditions: Breast Cancer Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting	Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer Conditions: Breast Cancer Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting	Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer Conditions: Breast Cancer Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting	Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer Conditions: Breast Cancer Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting	Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer Conditions: Breast Cancer Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting	Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer Conditions: Breast Cancer Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting	Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer Conditions: Breast Cancer Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting	Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer Conditions: Breast Cancer Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting	Prospective Urban Rural Epidemiology Study Conditions: Cardiovascular Diseases Risk Factor, Cardiovascular Health Behavior Environmental Exposure Lung Diseases Cancer Injuries Renal Disease Communicable Disease Sponsor: Population Health Research Institute Canadian Institutes of Health Research (CIHR) Heart and Stroke Foundation of Ontario
Recruiting	Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Conditions: Carcinoma In Situ Hematopoietic and Lymphoid System Neoplasm Malignant Solid Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Conditions: Carcinoma In Situ Hematopoietic and Lymphoid System Neoplasm Malignant Solid Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Conditions: Carcinoma In Situ Hematopoietic and Lymphoid System Neoplasm Malignant Solid Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Conditions: Carcinoma In Situ Hematopoietic and Lymphoid System Neoplasm Malignant Solid Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Conditions: Carcinoma In Situ Hematopoietic and Lymphoid System Neoplasm Malignant Solid Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Conditions: Carcinoma In Situ Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Conditions: Carcinoma In Situ Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Conditions: Carcinoma In Situ Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Conditions: Carcinoma In Situ Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Conditions: Carcinoma In Situ Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Conditions: Carcinoma In Situ Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Conditions: Carcinoma In Situ Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Conditions: Carcinoma In Situ Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Conditions: Carcinoma In Situ Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Conditions: Carcinoma In Situ Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Conditions: Carcinoma In Situ Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Biomarker Guided Discharge of Heart Failure Patients Conditions: Heart Failure With Decompensation Sponsor: Peter Liu Genome Canada Roche Diagnostics Ottawa Heart Institute Research Corporation
Recruiting	Biomarker Guided Discharge of Heart Failure Patients Conditions: Heart Failure With Decompensation Sponsor: Peter Liu Genome Canada Roche Diagnostics Ottawa Heart Institute Research Corporation
Recruiting	Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Conditions: Childhood Extracranial Germ Cell Tumor Extragonadal Embryonal Carcinoma Germ Cell Tumor Malignant Germ Cell Tumor Malignant Ovarian Teratoma Stage I Ovarian Choriocarcinoma Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage I Ovarian Teratoma AJCC v6 and v7 Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage I Testicular Choriocarcinoma AJCC v6 and v7 Stage I Testicular Embryonal Carcinoma AJCC v6 and v7 Stage I Testicular Seminoma AJCC v6 and v7 Stage I Testicular Yolk Sac Tumor AJCC v6 and v7 Stage II Ovarian Choriocarcinoma Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage II Testicular Choriocarcinoma AJCC v6 and v7 Stage II Testicular Embryonal Carcinoma AJCC v6 and v7 Stage II Testicular Yolk Sac Tumor AJCC v6 and v7 Stage III Ovarian Choriocarcinoma Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage III Testicular Choriocarcinoma AJCC v6 and v7 Stage III Testicular Embryonal Carcinoma AJCC v6 and v7 Stage III Testicular Yolk Sac Tumor AJCC v6 and v7 Stage IV Ovarian Choriocarcinoma Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7 Testicular Mixed Choriocarcinoma and Embryonal Carcinoma Testicular Mixed Choriocarcinoma and Teratoma Testicular Mixed Choriocarcinoma and Yolk Sac Tumor Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Conditions: Childhood Extracranial Germ Cell Tumor Extragonadal Embryonal Carcinoma Germ Cell Tumor Malignant Germ Cell Tumor Malignant Ovarian Teratoma Stage I Ovarian Choriocarcinoma Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage I Ovarian Teratoma AJCC v6 and v7 Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage I Testicular Choriocarcinoma AJCC v6 and v7 Stage I Testicular Embryonal Carcinoma AJCC v6 and v7 Stage I Testicular Seminoma AJCC v6 and v7 Stage I Testicular Yolk Sac Tumor AJCC v6 and v7 Stage II Ovarian Choriocarcinoma Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage II Testicular Choriocarcinoma AJCC v6 and v7 Stage II Testicular Embryonal Carcinoma AJCC v6 and v7 Stage II Testicular Yolk Sac Tumor AJCC v6 and v7 Stage III Ovarian Choriocarcinoma Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage III Testicular Choriocarcinoma AJCC v6 and v7 Stage III Testicular Embryonal Carcinoma AJCC v6 and v7 Stage III Testicular Yolk Sac Tumor AJCC v6 and v7 Stage IV Ovarian Choriocarcinoma Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7 Testicular Mixed Choriocarcinoma and Embryonal Carcinoma Testicular Mixed Choriocarcinoma and Teratoma Testicular Mixed Choriocarcinoma and Yolk Sac Tumor Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Conditions: Childhood Extracranial Germ Cell Tumor Extragonadal Embryonal Carcinoma Germ Cell Tumor Malignant Germ Cell Tumor Malignant Ovarian Teratoma Stage I Ovarian Choriocarcinoma Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage I Ovarian Teratoma AJCC v6 and v7 Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage I Testicular Choriocarcinoma AJCC v6 and v7 Stage I Testicular Embryonal Carcinoma AJCC v6 and v7 Stage I Testicular Seminoma AJCC v6 and v7 Stage I Testicular Yolk Sac Tumor AJCC v6 and v7 Stage II Ovarian Choriocarcinoma Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage II Testicular Choriocarcinoma AJCC v6 and v7 Stage II Testicular Embryonal Carcinoma AJCC v6 and v7 Stage II Testicular Yolk Sac Tumor AJCC v6 and v7 Stage III Ovarian Choriocarcinoma Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage III Testicular Choriocarcinoma AJCC v6 and v7 Stage III Testicular Embryonal Carcinoma AJCC v6 and v7 Stage III Testicular Yolk Sac Tumor AJCC v6 and v7 Stage IV Ovarian Choriocarcinoma Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7 Testicular Mixed Choriocarcinoma and Embryonal Carcinoma Testicular Mixed Choriocarcinoma and Teratoma Testicular Mixed Choriocarcinoma and Yolk Sac Tumor Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Conditions: Childhood Extracranial Germ Cell Tumor Extragonadal Embryonal Carcinoma Germ Cell Tumor Malignant Germ Cell Tumor Malignant Ovarian Teratoma Stage I Ovarian Choriocarcinoma Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage I Ovarian Teratoma AJCC v6 and v7 Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage I Testicular Choriocarcinoma AJCC v6 and v7 Stage I Testicular Embryonal Carcinoma AJCC v6 and v7 Stage I Testicular Seminoma AJCC v6 and v7 Stage I Testicular Yolk Sac Tumor AJCC v6 and v7 Stage II Ovarian Choriocarcinoma Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage II Testicular Choriocarcinoma AJCC v6 and v7 Stage II Testicular Embryonal Carcinoma AJCC v6 and v7 Stage II Testicular Yolk Sac Tumor AJCC v6 and v7 Stage III Ovarian Choriocarcinoma Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage III Testicular Choriocarcinoma AJCC v6 and v7 Stage III Testicular Embryonal Carcinoma AJCC v6 and v7 Stage III Testicular Yolk Sac Tumor AJCC v6 and v7 Stage IV Ovarian Choriocarcinoma Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7 Testicular Mixed Choriocarcinoma and Embryonal Carcinoma Testicular Mixed Choriocarcinoma and Teratoma Testicular Mixed Choriocarcinoma and Yolk Sac Tumor Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Conditions: Childhood Extracranial Germ Cell Tumor Extragonadal Embryonal Carcinoma Germ Cell Tumor Malignant Germ Cell Tumor Malignant Ovarian Teratoma Stage I Ovarian Choriocarcinoma Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage I Ovarian Teratoma AJCC v6 and v7 Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage I Testicular Choriocarcinoma AJCC v6 and v7 Stage I Testicular Embryonal Carcinoma AJCC v6 and v7 Stage I Testicular Seminoma AJCC v6 and v7 Stage I Testicular Yolk Sac Tumor AJCC v6 and v7 Stage II Ovarian Choriocarcinoma Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage II Testicular Choriocarcinoma AJCC v6 and v7 Stage II Testicular Embryonal Carcinoma AJCC v6 and v7 Stage II Testicular Yolk Sac Tumor AJCC v6 and v7 Stage III Ovarian Choriocarcinoma Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage III Testicular Choriocarcinoma AJCC v6 and v7 Stage III Testicular Embryonal Carcinoma AJCC v6 and v7 Stage III Testicular Yolk Sac Tumor AJCC v6 and v7 Stage IV Ovarian Choriocarcinoma Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7 Testicular Mixed Choriocarcinoma and Embryonal Carcinoma Testicular Mixed Choriocarcinoma and Teratoma Testicular Mixed Choriocarcinoma and Yolk Sac Tumor Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Conditions: Childhood Extracranial Germ Cell Tumor Extragonadal Embryonal Carcinoma Germ Cell Tumor Malignant Germ Cell Tumor Malignant Ovarian Teratoma Stage I Ovarian Choriocarcinoma Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage I Ovarian Teratoma AJCC v6 and v7 Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage I Testicular Choriocarcinoma AJCC v6 and v7 Stage I Testicular Embryonal Carcinoma AJCC v6 and v7 Stage I Testicular Seminoma AJCC v6 and v7 Stage I Testicular Yolk Sac Tumor AJCC v6 and v7 Stage II Ovarian Choriocarcinoma Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage II Testicular Choriocarcinoma AJCC v6 and v7 Stage II Testicular Embryonal Carcinoma AJCC v6 and v7 Stage II Testicular Yolk Sac Tumor AJCC v6 and v7 Stage III Ovarian Choriocarcinoma Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage III Testicular Choriocarcinoma AJCC v6 and v7 Stage III Testicular Embryonal Carcinoma AJCC v6 and v7 Stage III Testicular Yolk Sac Tumor AJCC v6 and v7 Stage IV Ovarian Choriocarcinoma Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7 Testicular Mixed Choriocarcinoma and Embryonal Carcinoma Testicular Mixed Choriocarcinoma and Teratoma Testicular Mixed Choriocarcinoma and Yolk Sac Tumor Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Conditions: Childhood Extracranial Germ Cell Tumor Extragonadal Embryonal Carcinoma Germ Cell Tumor Malignant Germ Cell Tumor Malignant Ovarian Teratoma Stage I Ovarian Choriocarcinoma Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage I Ovarian Teratoma AJCC v6 and v7 Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage I Testicular Choriocarcinoma AJCC v6 and v7 Stage I Testicular Embryonal Carcinoma AJCC v6 and v7 Stage I Testicular Seminoma AJCC v6 and v7 Stage I Testicular Yolk Sac Tumor AJCC v6 and v7 Stage II Ovarian Choriocarcinoma Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage II Testicular Choriocarcinoma AJCC v6 and v7 Stage II Testicular Embryonal Carcinoma AJCC v6 and v7 Stage II Testicular Yolk Sac Tumor AJCC v6 and v7 Stage III Ovarian Choriocarcinoma Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage III Testicular Choriocarcinoma AJCC v6 and v7 Stage III Testicular Embryonal Carcinoma AJCC v6 and v7 Stage III Testicular Yolk Sac Tumor AJCC v6 and v7 Stage IV Ovarian Choriocarcinoma Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7 Testicular Mixed Choriocarcinoma and Embryonal Carcinoma Testicular Mixed Choriocarcinoma and Teratoma Testicular Mixed Choriocarcinoma and Yolk Sac Tumor Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Conditions: Childhood Extracranial Germ Cell Tumor Extragonadal Embryonal Carcinoma Germ Cell Tumor Malignant Germ Cell Tumor Malignant Ovarian Teratoma Stage I Ovarian Choriocarcinoma Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage I Ovarian Teratoma AJCC v6 and v7 Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage I Testicular Choriocarcinoma AJCC v6 and v7 Stage I Testicular Embryonal Carcinoma AJCC v6 and v7 Stage I Testicular Seminoma AJCC v6 and v7 Stage I Testicular Yolk Sac Tumor AJCC v6 and v7 Stage II Ovarian Choriocarcinoma Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage II Testicular Choriocarcinoma AJCC v6 and v7 Stage II Testicular Embryonal Carcinoma AJCC v6 and v7 Stage II Testicular Yolk Sac Tumor AJCC v6 and v7 Stage III Ovarian Choriocarcinoma Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage III Testicular Choriocarcinoma AJCC v6 and v7 Stage III Testicular Embryonal Carcinoma AJCC v6 and v7 Stage III Testicular Yolk Sac Tumor AJCC v6 and v7 Stage IV Ovarian Choriocarcinoma Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7 Testicular Mixed Choriocarcinoma and Embryonal Carcinoma Testicular Mixed Choriocarcinoma and Teratoma Testicular Mixed Choriocarcinoma and Yolk Sac Tumor Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Conditions: Childhood Extracranial Germ Cell Tumor Extragonadal Embryonal Carcinoma Germ Cell Tumor Malignant Germ Cell Tumor Malignant Ovarian Teratoma Stage I Ovarian Choriocarcinoma Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage I Ovarian Teratoma AJCC v6 and v7 Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage I Testicular Choriocarcinoma AJCC v6 and v7 Stage I Testicular Embryonal Carcinoma AJCC v6 and v7 Stage I Testicular Seminoma AJCC v6 and v7 Stage I Testicular Yolk Sac Tumor AJCC v6 and v7 Stage II Ovarian Choriocarcinoma Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage II Testicular Choriocarcinoma AJCC v6 and v7 Stage II Testicular Embryonal Carcinoma AJCC v6 and v7 Stage II Testicular Yolk Sac Tumor AJCC v6 and v7 Stage III Ovarian Choriocarcinoma Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage III Testicular Choriocarcinoma AJCC v6 and v7 Stage III Testicular Embryonal Carcinoma AJCC v6 and v7 Stage III Testicular Yolk Sac Tumor AJCC v6 and v7 Stage IV Ovarian Choriocarcinoma Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7 Testicular Mixed Choriocarcinoma and Embryonal Carcinoma Testicular Mixed Choriocarcinoma and Teratoma Testicular Mixed Choriocarcinoma and Yolk Sac Tumor Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Conditions: Childhood Extracranial Germ Cell Tumor Extragonadal Embryonal Carcinoma Germ Cell Tumor Malignant Germ Cell Tumor Malignant Ovarian Teratoma Stage I Ovarian Choriocarcinoma Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage I Ovarian Teratoma AJCC v6 and v7 Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage I Testicular Choriocarcinoma AJCC v6 and v7 Stage I Testicular Embryonal Carcinoma AJCC v6 and v7 Stage I Testicular Seminoma AJCC v6 and v7 Stage I Testicular Yolk Sac Tumor AJCC v6 and v7 Stage II Ovarian Choriocarcinoma Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage II Testicular Choriocarcinoma AJCC v6 and v7 Stage II Testicular Embryonal Carcinoma AJCC v6 and v7 Stage II Testicular Yolk Sac Tumor AJCC v6 and v7 Stage III Ovarian Choriocarcinoma Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage III Testicular Choriocarcinoma AJCC v6 and v7 Stage III Testicular Embryonal Carcinoma AJCC v6 and v7 Stage III Testicular Yolk Sac Tumor AJCC v6 and v7 Stage IV Ovarian Choriocarcinoma Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7 Testicular Mixed Choriocarcinoma and Embryonal Carcinoma Testicular Mixed Choriocarcinoma and Teratoma Testicular Mixed Choriocarcinoma and Yolk Sac Tumor Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting	Comparing Hypothermic Temperatures During Hemiarch Surgery Conditions: Thoracic Aortic Disease Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	Comparing Hypothermic Temperatures During Hemiarch Surgery Conditions: Thoracic Aortic Disease Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	Comparing Hypothermic Temperatures During Hemiarch Surgery Conditions: Thoracic Aortic Disease Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	Comparing Hypothermic Temperatures During Hemiarch Surgery Conditions: Thoracic Aortic Disease Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	Comparing Hypothermic Temperatures During Hemiarch Surgery Conditions: Thoracic Aortic Disease Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	Comparing Hypothermic Temperatures During Hemiarch Surgery Conditions: Thoracic Aortic Disease Sponsor: Ottawa Heart Institute Research Corporation
Recruiting	Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Conditions: Community-acquired Pneumonia, Influenza, COVID-19 Sponsor: UMC Utrecht Australian and New Zealand Intensive Care Research Centre Medical Research Institute of New Zealand Unity Health Berry Consultants Global Coalition for Adaptive Research University of Pittsburgh Medical Center Intensive Care National Audit & Research Centre St. Marianna University School of Medicine National Intensive Care Surveillance MORU National University Hospital, Singapore
Recruiting	Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Conditions: Community-acquired Pneumonia, Influenza, COVID-19 Sponsor: UMC Utrecht Australian and New Zealand Intensive Care Research Centre Medical Research Institute of New Zealand Unity Health Berry Consultants Global Coalition for Adaptive Research University of Pittsburgh Medical Center Intensive Care National Audit & Research Centre St. Marianna University School of Medicine National Intensive Care Surveillance MORU National University Hospital, Singapore
Recruiting	Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Conditions: Community-acquired Pneumonia, Influenza, COVID-19 Sponsor: UMC Utrecht Australian and New Zealand Intensive Care Research Centre Medical Research Institute of New Zealand Unity Health Berry Consultants Global Coalition for Adaptive Research University of Pittsburgh Medical Center Intensive Care National Audit & Research Centre St. Marianna University School of Medicine National Intensive Care Surveillance MORU National University Hospital, Singapore
Recruiting	Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Conditions: Community-acquired Pneumonia, Influenza, COVID-19 Sponsor: UMC Utrecht Australian and New Zealand Intensive Care Research Centre Medical Research Institute of New Zealand Unity Health Berry Consultants Global Coalition for Adaptive Research University of Pittsburgh Medical Center Intensive Care National Audit & Research Centre St. Marianna University School of Medicine National Intensive Care Surveillance MORU National University Hospital, Singapore
Recruiting	Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Conditions: Community-acquired Pneumonia, Influenza, COVID-19 Sponsor: UMC Utrecht Australian and New Zealand Intensive Care Research Centre Medical Research Institute of New Zealand Unity Health Berry Consultants Global Coalition for Adaptive Research University of Pittsburgh Medical Center Intensive Care National Audit & Research Centre St. Marianna University School of Medicine National Intensive Care Surveillance MORU National University Hospital, Singapore
Recruiting	Project: Every Child for Younger Patients With Cancer Conditions: Carcinoma In Situ Central Nervous System Neoplasm Childhood Immature Teratoma Childhood Langerhans Cell Histiocytosis Childhood Mature Teratoma Congenital Mesoblastic Nephroma Desmoid Fibromatosis Ganglioneuroma Lymphoproliferative Disorder Malignant Solid Neoplasm Melanocytic Neoplasm Myeloproliferative Neoplasm Neuroendocrine Neoplasm Stromal Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Project: Every Child for Younger Patients With Cancer Conditions: Carcinoma In Situ Central Nervous System Neoplasm Childhood Immature Teratoma Childhood Langerhans Cell Histiocytosis Childhood Mature Teratoma Congenital Mesoblastic Nephroma Desmoid Fibromatosis Ganglioneuroma Lymphoproliferative Disorder Malignant Solid Neoplasm Melanocytic Neoplasm Myeloproliferative Neoplasm Neuroendocrine Neoplasm Stromal Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Project: Every Child for Younger Patients With Cancer Conditions: Carcinoma In Situ Central Nervous System Neoplasm Childhood Immature Teratoma Childhood Langerhans Cell Histiocytosis Childhood Mature Teratoma Congenital Mesoblastic Nephroma Desmoid Fibromatosis Ganglioneuroma Lymphoproliferative Disorder Malignant Solid Neoplasm Melanocytic Neoplasm Myeloproliferative Neoplasm Neuroendocrine Neoplasm Stromal Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Project: Every Child for Younger Patients With Cancer Conditions: Carcinoma In Situ Central Nervous System Neoplasm Childhood Immature Teratoma Childhood Langerhans Cell Histiocytosis Childhood Mature Teratoma Congenital Mesoblastic Nephroma Desmoid Fibromatosis Ganglioneuroma Lymphoproliferative Disorder Malignant Solid Neoplasm Melanocytic Neoplasm Myeloproliferative Neoplasm Neuroendocrine Neoplasm Stromal Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Project: Every Child for Younger Patients With Cancer Conditions: Carcinoma In Situ Central Nervous System Neoplasm Childhood Immature Teratoma Childhood Langerhans Cell Histiocytosis Childhood Mature Teratoma Congenital Mesoblastic Nephroma Desmoid Fibromatosis Ganglioneuroma Lymphoproliferative Disorder Malignant Solid Neoplasm Melanocytic Neoplasm Myeloproliferative Neoplasm Neuroendocrine Neoplasm Stromal Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment Conditions: Hodgkin Lymphoma in Remission Leukemia in Remission Lymphoblastic Lymphoma Osteosarcoma Recurrent Leukemia Recurrent Lymphoma Recurrent Malignant Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment Conditions: Hodgkin Lymphoma in Remission Leukemia in Remission Lymphoblastic Lymphoma Osteosarcoma Recurrent Leukemia Recurrent Lymphoma Recurrent Malignant Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment Conditions: Hodgkin Lymphoma in Remission Leukemia in Remission Lymphoblastic Lymphoma Osteosarcoma Recurrent Leukemia Recurrent Lymphoma Recurrent Malignant Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment Conditions: Hodgkin Lymphoma in Remission Leukemia in Remission Lymphoblastic Lymphoma Osteosarcoma Recurrent Leukemia Recurrent Lymphoma Recurrent Malignant Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment Conditions: Hodgkin Lymphoma in Remission Leukemia in Remission Lymphoblastic Lymphoma Osteosarcoma Recurrent Leukemia Recurrent Lymphoma Recurrent Malignant Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment Conditions: Hodgkin Lymphoma in Remission Leukemia in Remission Lymphoblastic Lymphoma Osteosarcoma Recurrent Leukemia Recurrent Lymphoma Recurrent Malignant Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment Conditions: Hodgkin Lymphoma in Remission Leukemia in Remission Lymphoblastic Lymphoma Osteosarcoma Recurrent Leukemia Recurrent Lymphoma Recurrent Malignant Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Conditions: Ganglioneuroblastoma Localized Resectable Neuroblastoma Localized Unresectable Neuroblastoma Regional Neuroblastoma Stage 4 Neuroblastoma Stage 4S Neuroblastoma Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Conditions: Ganglioneuroblastoma Localized Resectable Neuroblastoma Localized Unresectable Neuroblastoma Regional Neuroblastoma Stage 4 Neuroblastoma Stage 4S Neuroblastoma Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Neuropsychological and Behavioral Testing in Younger Patients With Cancer Conditions: Childhood Malignant Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Neuropsychological and Behavioral Testing in Younger Patients With Cancer Conditions: Childhood Malignant Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Neuropsychological and Behavioral Testing in Younger Patients With Cancer Conditions: Childhood Malignant Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Neuropsychological and Behavioral Testing in Younger Patients With Cancer Conditions: Childhood Malignant Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Neuropsychological and Behavioral Testing in Younger Patients With Cancer Conditions: Childhood Malignant Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction Conditions: Myocardial Infarction Sudden Death Sponsor: University of Calgary Canadian Institutes of Health Research (CIHR) Alberta Innovation and Science Medtronic GE Healthcare Cardiac Arrhythmia Network of Canada Accelerating Clinical Trials Consortium
Recruiting	Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction Conditions: Myocardial Infarction Sudden Death Sponsor: University of Calgary Canadian Institutes of Health Research (CIHR) Alberta Innovation and Science Medtronic GE Healthcare Cardiac Arrhythmia Network of Canada Accelerating Clinical Trials Consortium
Recruiting	Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction Conditions: Myocardial Infarction Sudden Death Sponsor: University of Calgary Canadian Institutes of Health Research (CIHR) Alberta Innovation and Science Medtronic GE Healthcare Cardiac Arrhythmia Network of Canada Accelerating Clinical Trials Consortium
Recruiting	Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction Conditions: Myocardial Infarction Sudden Death Sponsor: University of Calgary Canadian Institutes of Health Research (CIHR) Alberta Innovation and Science Medtronic GE Healthcare Cardiac Arrhythmia Network of Canada Accelerating Clinical Trials Consortium
Recruiting	Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction Conditions: Myocardial Infarction Sudden Death Sponsor: University of Calgary Canadian Institutes of Health Research (CIHR) Alberta Innovation and Science Medtronic GE Healthcare Cardiac Arrhythmia Network of Canada Accelerating Clinical Trials Consortium
Recruiting	Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors Conditions: Childhood Malignant Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors Conditions: Childhood Malignant Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors Conditions: Childhood Malignant Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors Conditions: Childhood Malignant Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting	Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors Conditions: Childhood Malignant Neoplasm Sponsor: Children's Oncology Group National Cancer Institute (NCI)